Abstract
To enable antibodies to function as cytotoxic anticancer agents, they are modified either via attachment to protein toxins or highly potent, low-molecular-weight drugs. Such molecules, termed immunotoxins and antibody-drug conjugates, respectively, represent a second revolution in antibody-mediated cancer therapy. Thus, highly toxic compounds are delivered to the interior of cancer cells based on antibody specificity for cell-surface target antigens.
Publication types
-
Research Support, N.I.H., Intramural
-
Research Support, Non-U.S. Gov't
-
Review
MeSH terms
-
Animals
-
Antigens, CD / immunology
-
Antigens, CD19 / immunology
-
Antigens, Differentiation, Myelomonocytic / immunology
-
Antineoplastic Agents / immunology
-
Antineoplastic Agents / therapeutic use*
-
Bacterial Toxins / therapeutic use
-
CD3 Complex / immunology
-
Clinical Trials as Topic
-
Exotoxins / therapeutic use
-
Hematologic Neoplasms / drug therapy*
-
Hematologic Neoplasms / immunology
-
Humans
-
Immunotoxins / chemistry
-
Immunotoxins / immunology
-
Immunotoxins / therapeutic use*
-
Interleukin-3 Receptor alpha Subunit / immunology
-
Mice
-
Receptors, Interleukin-2 / immunology
-
Sialic Acid Binding Ig-like Lectin 2 / immunology
-
Sialic Acid Binding Ig-like Lectin 3
-
Syndecan-1 / immunology
Substances
-
Antigens, CD
-
Antigens, CD19
-
Antigens, Differentiation, Myelomonocytic
-
Antineoplastic Agents
-
Bacterial Toxins
-
CD22 protein, human
-
CD3 Complex
-
CD33 protein, human
-
Cd33 protein, mouse
-
Exotoxins
-
IL3RA protein, human
-
Immunotoxins
-
Interleukin-3 Receptor alpha Subunit
-
Receptors, Interleukin-2
-
SDC1 protein, human
-
Sialic Acid Binding Ig-like Lectin 2
-
Sialic Acid Binding Ig-like Lectin 3
-
Syndecan-1
-
immunotoxin HA22